Artificial Intelligence algorithm predicts long-term kidney transplant outcomes
BRISBANE, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announces that the iBox validation study from the Paris Transplant Group has been published in the British Medical Journal (BMJ).
CareDx launched KidneyCare at the American Transplant Congress in June 2019. KidneyCare includes the iBox technology as a prognostic measurement alongside multimodality testing with AlloSure® and AlloMap®. CareDx holds the exclusive rights to commercialize the iBox algorithm in the US, through its partnership with Cibiltech, a Paris-based medical technology company.
“Our BMJ publication shows the algorithm we created can provide standardization across centers worldwide,” said Alexandre Loupy, MD, Director of the Paris Transplant Group. “The iBox risk prediction score may help guide patient monitoring and further improve the design and the development of a valid and early surrogate endpoint for clinical trials.”
The BMJ study’s aim was to validate the iBox integrative system to predict long-term allograft failure. The study assessed the performance of the iBox risk prediction score in 7,557 kidney transplant recipients with a median follow-up time of 7 years, across 10 academic medical centers from the United States and Europe. The iBox risk prediction score combines allograft function, histological and immunological parameters with HLA donor specific antibody profiling, to accurately predict the risk of long-term kidney allograft failure as well as to identify significant changes at the time of therapeutic interventions.
“Transplantation provides an incredibly rich data set and is ripe for using augmented intelligence tools to better assess risk and help physicians better manage their daily patient care. Our next step is clinical utility, which we capture through our OKRA registry measuring outcomes from patients surveilled with KidneyCare,” said Sham Dholakia, MD, DPhil, CareDx’s Senior Vice President of Medical Affairs & Clinical Operations.
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients.
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements, including statements regarding iBox. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, among others discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed by CareDx with the SEC on March 6, 2019 and the periodic reports that CareDx has subsequently filed with the SEC. Any of these may cause CareDx’s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Chief Marketing Officer, CareDx Inc.
Chief Financial Officer, CareDx Inc.